In C9ORF72 mutant hiPSC-MN, antisense oligonucleotides (ASOs) against C9ORF72 also decreased ALS-associated pathology, which has led to clinical trials [186,187]. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.